Shares of Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report) were up 7.3% on Thursday . The stock traded as high as $0.48 and last traded at $0.44. Approximately 25,779 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 573,537 shares. The stock had previously closed at $0.41.
Analyst Ratings Changes
Separately, Roth Mkm restated a “buy” rating on shares of Panbela Therapeutics in a research note on Wednesday, March 27th.
Read Our Latest Analysis on PBLA
Panbela Therapeutics Stock Performance
Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) last issued its earnings results on Tuesday, March 26th. The company reported ($65.90) EPS for the quarter, missing the consensus estimate of ($24.34) by ($41.56). Research analysts forecast that Panbela Therapeutics, Inc. will post -5.25 EPS for the current year.
Panbela Therapeutics Company Profile
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase.
See Also
- Five stocks we like better than Panbela Therapeutics
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- MarketBeat Week in Review – 4/22 – 4/26
- How to Choose Top Rated Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Are the FAANG Stocks and Are They Good Investments?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.